TRPV1 nociceptors in oral carcinogenesis and pain

TRPV1 伤害感受器在口腔癌发生和疼痛中的作用

基本信息

  • 批准号:
    10358603
  • 负责人:
  • 金额:
    $ 62.74万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-03-01 至 2026-02-28
  • 项目状态:
    未结题

项目摘要

Project Summary Oral cancer pain is more severe than all other cancers. Patients with metastatic oral cancer experience the greatest pain. Oral cancers activate neurons and produce pain; however, the effect of nociceptors on oral cancer is largely unknown. The mechanisms of reciprocal interaction between oral cancer and neurons, and how the interactions promote cancer and pain, are not known. The long-term goal is to improve management of oral cancer patients and obviate opioids by identifying components of the cancer microenvironment that are viable targets to treat cancer and oral cancer pain. The overall objectives for this application are to (i) elucidate the phenotype and distribution of transient receptor potential channel, vanilloid subfamily member (TRPV1) + neurons innervating painful and metastatic oral cancers, (ii) measure sensitization and activation of TRPV1+ neurons by mediators secreted by oral cancer, and (iii) determine the contribution of TRPV1+ neurons to oral carcinogenesis. The central hypothesis is that oral cancers release mediators, including mediators carried in extracellular vesicles (EVs) that sensitize and activate nociceptors inducing oral cancer pain. The cancer- primed nociceptors, in turn, promote cancer. The rationale for the project is that identification of components of the cancer-nerve interaction provides the opportunity to develop approaches to treat oral cancer and oral cancer pain, thereby reducing use of opioids. The central hypothesis will be tested by pursuing three specific aims: 1) Determine the type and density of innervation in oral cancers in relation to pain and metastasis; 2) Investigate sensitization of trigeminal (TG) neurons by cancer pain mediators; and, 3) Investigate cancer promotion by cancer activated and sensitized TRPV1+ neurons and evaluate the potential to stop cancer and alleviate cancer pain by antagonizing signaling via the sensory neuropeptide, calcitonin gene related peptide (CGRP). Under the first aim, neuronal innervation of the cancer will be evaluated in a retrospective patient cohort with known pain and nodal status, and testing for capsaicin (TRPV1 agonist) sensitivity and measurement of pain will be performed in prospectively enrolled oral cancer patients. For the second aim, a gene associated with pain and metastasis and miRNAs from EVs will be investigated as pain mediators. For the third aim a mouse oral carcinogenesis model will be used to investigate the impact of TRPV1 abundance on cancer incidence and phenotype, the impact of CGRP signaling on cancer promotion, and the potential for CGRP/CGRP receptor therapies for treating and preventing oral cancer and oral cancer pain. The research proposed is innovative because it is based on two new findings regarding oral cancer pain: (1) newly identified putative cancer pain mediators overexpressed in metastatic cancers from patients reporting high levels of pain, and (2) involvement of EVs in cancer induced nociceptive behavior. The proposed research is significant because these studies will lay the foundation for clinical trials to assess CGRP and CGRP receptor targeted therapies, which are FDA-approved for migraine, to treat cancer and attenuate cancer pain.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Donna G Albertson其他文献

Chromosome aberrations in solid tumors
实体瘤中的染色体畸变
  • DOI:
    10.1038/ng1215
  • 发表时间:
    2003-07-30
  • 期刊:
  • 影响因子:
    29.000
  • 作者:
    Donna G Albertson;Colin Collins;Frank McCormick;Joe W Gray
  • 通讯作者:
    Joe W Gray
Conflicting evidence on the frequency of ESR1 amplification in breast cancer
关于乳腺癌中 ESR1 扩增频率的相互矛盾的证据
  • DOI:
    10.1038/ng0708-821
  • 发表时间:
    2008-07-01
  • 期刊:
  • 影响因子:
    29.000
  • 作者:
    Donna G Albertson
  • 通讯作者:
    Donna G Albertson

Donna G Albertson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Donna G Albertson', 18)}}的其他基金

TRPV1 nociceptors in oral carcinogenesis and pain
TRPV1 伤害感受器在口腔癌发生和疼痛中的作用
  • 批准号:
    10173219
  • 财政年份:
    2021
  • 资助金额:
    $ 62.74万
  • 项目类别:
TRPV1 nociceptors in oral carcinogenesis and pain
TRPV1 伤害感受器在口腔癌发生和疼痛中的作用
  • 批准号:
    10600862
  • 财政年份:
    2021
  • 资助金额:
    $ 62.74万
  • 项目类别:
Artemin overexpression in oral cancer pain and carcinogenesis
Artemin 过度表达在口腔癌疼痛和癌变中的作用
  • 批准号:
    10475175
  • 财政年份:
    2019
  • 资助金额:
    $ 62.74万
  • 项目类别:
Artemin overexpression in oral cancer pain and carcinogenesis
Artemin 过度表达在口腔癌疼痛和癌变中的作用
  • 批准号:
    10242843
  • 财政年份:
    2019
  • 资助金额:
    $ 62.74万
  • 项目类别:
Artemin overexpression in oral cancer pain and carcinogenesis
Artemin 过度表达在口腔癌疼痛和癌变中的作用
  • 批准号:
    10700882
  • 财政年份:
    2019
  • 资助金额:
    $ 62.74万
  • 项目类别:
A DNA biomarker of oral cancer metastasis
口腔癌转移的 DNA 生物标志物
  • 批准号:
    8598730
  • 财政年份:
    2013
  • 资助金额:
    $ 62.74万
  • 项目类别:
FISH assay identifying oral cancer patients at low risk of lymph node metastasis
FISH 检测可识别淋巴结转移风险较低的口腔癌患者
  • 批准号:
    8719677
  • 财政年份:
    2012
  • 资助金额:
    $ 62.74万
  • 项目类别:
FISH assay identifying oral cancer patients at low risk of lymph node metastasis
FISH 检测可识别淋巴结转移风险较低的口腔癌患者
  • 批准号:
    8442841
  • 财政年份:
    2012
  • 资助金额:
    $ 62.74万
  • 项目类别:
FISH assay identifying oral cancer patients at low risk of lymph node metastasis
FISH 检测可识别淋巴结转移风险较低的口腔癌患者
  • 批准号:
    8257685
  • 财政年份:
    2012
  • 资助金额:
    $ 62.74万
  • 项目类别:
Amplicons in Oral Dysplasia
口腔发育不良中的扩增子
  • 批准号:
    7683090
  • 财政年份:
    2008
  • 资助金额:
    $ 62.74万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 62.74万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 62.74万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 62.74万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 62.74万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 62.74万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 62.74万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 62.74万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 62.74万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 62.74万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 62.74万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了